文献速递乳腺癌放疗

乳腺癌淋巴结阳性患者的大分割区域淋巴结放疗

Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-15

毒性以纤维化30.7%、色素沉着19.2%、毛细血管扩张12.3%为主,≥2级淋巴水肿5.8%,未观察到心脏或症状性肺炎。作者认为大分割区域淋巴结放疗似为可接受的替代方案,但需前瞻性随机试验确认。

要点

  • 5年OS 86.6%、DFS 84.4%、LRR无生存93.9%、DM无生存83.1%。
  • 纤维化30.7%、色素沉着19.2%、毛细血管扩张12.3%、≥2级淋巴水肿5.8%。
  • 未观察到心脏毒性、症状性肺炎、臂丛病或肋骨骨折。

核心结论

  • 该回顾性研究提示大分割区域淋巴结放疗似为需要区域淋巴结照射的乳腺癌患者的可接受替代方案。
  • 作者指出需前瞻性随机试验确认这些初步结果。

研究设计与样本

  • 51例(19.8%)行保乳手术后放疗,206例(80.2%)行根治性手术后放疗;保乳患者接受瘤床加量(光子、电子或组织间高剂量率近距离治疗)。
  • 中位随访64个月(范围11-88个月)。

主要发现

  • 5年OS、DFS、LRR无生存和DM无生存分别为86.6%、84.4%、93.9%和83.1%。
  • 多因素分析中,淋巴结比率>65%、脉管侵犯和激素受体阴性预测OS、DFS和DM。
  • T3-4期也与较差的DFS和DM相关。
  • LRR的多因素独立预后因素为N2-3期和3级。
  • 色素沉着发生率19.2%,毛细血管扩张12.3%,纤维化30.7%,≥2级淋巴水肿5.8%;随访期间未观察到心脏毒性、症状性肺炎、臂丛病或肋骨骨折。

临床怎么用

  • 对于需要区域淋巴结照射的淋巴结阳性乳腺癌患者,可考虑大分割区域淋巴结放疗(42 Gy/15次)作为替代方案。
  • 治疗决策时应结合淋巴结比率、脉管侵犯、激素受体状态、T分期、N分期和分级等预后因素综合评估。
  • 需向患者告知纤维化、色素沉着、毛细血管扩张和淋巴水肿等毒性风险。

局限性

  • 作者明确指出需前瞻性随机试验确认这些初步结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of hypofractionated radiation therapy (HFRT) of the breast/chest wall and regional nodes on overall survival (OS), disease-free survival (DFS), locoregional control and on treatment-related toxicity in patients with breast cancer and nodal involvement. METHODS AND MATERIALS: Two hundred fifty-seven patients treated between October 2009 and June 2011 with hypofractionated locoregional radiation therapy (42 Gy in 15 fractions) were retrospectively reviewed, 51 (19.8%) after breast-conserving surgery and 206 (80.2%) after radical surgery. Patients treated with breast-conserving surgery received a boost dose to the tumor bed (delivered by photons, electrons, or interstitial high-dose-rate brachytherapy). Two hundred fifty-six (99.6%) patients underwent chemotherapy, 209 (81.3%) had hormonal treatment, and 65 (25.3%) had anti-HER2 targeted therapy. RESULTS: The median follow-up time was 64 months (range, 11-88 months). The rates of 5-year OS, DFS, locoregional recurrence (LRR)-free survival, and distant metastasis (DM)-free survival were 86.6%, 84.4%, 93.9%, and 83.1%, respectively. In multivariate analysis (MVA), lymph node ratio >65%, lymphovascular invasion, and negative hormone receptor status predicted for OS, DSF, and DM. T3 to 4 stage was also associated with worse DFS and DM. Finally, for LRR the independent prognostic factors on MVA were N2 to 3 stage and grade 3. Hyperpigmentation was observed in 19.2% of patients, telangiectasia in 12.3%, and fibrosis in 30.7%. Grade ≥2 lymphedema was recorded in 5.8% of cases. During the study follow-up, no cardiac or symptomatic pneumonitis was observed, nor were plexopathy or rib fractures. CONCLUSION: According to the findings from this retrospective study, HFRT seems to be an acceptable alternative for patients with breast cancer who need regional nodal irradiation. However, prospective randomized trials are necessary to confirm these preliminary results.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bellefqih S, Elmajjaoui S, Aarab J, et al. Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28126305. doi:10.1016/j.ijrobp.2016.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。